File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The Huashan risk calculators performed better in prediction of prostate cancer in Chinese population: A training study followed by a validation study

TitleThe Huashan risk calculators performed better in prediction of prostate cancer in Chinese population: A training study followed by a validation study
Authors
Keywordsbiopsy
China
prostate cancer
prostate-specific antigen
risk calculator
Issue Date2016
Citation
Asian Journal of Andrology, 2016, v. 18, n. 6, p. 925-929 How to Cite?
AbstractThe performances of the Prostate Cancer Prevention Trial (PCPT) risk calculator and other risk calculators for prostate cancer (PCa) prediction in Chinese populations were poorly understood. We performed this study to build risk calculators (Huashan risk calculators) based on Chinese population and validated the performance of prostate-specific antigen (PSA), PCPT risk calculator, and Huashan risk calculators in a validation cohort. We built Huashan risk calculators based on data from 1059 men who underwent initial prostate biopsy from January 2006 to December 2010 in a training cohort. Then, we validated the performance of PSA, PCPT risk calculator, and Huashan risk calculators in an observational validation study from January 2011 to December 2014. All necessary clinical information were collected before the biopsy. The results showed that Huashan risk calculators 1 and 2 outperformed the PCPT risk calculator for predicting PCa in both entire training cohort and stratified population (with PSA from 2.0 ng ml-1 to 20.0 ng m). In the validation study, Huashan risk calculator 1 still outperformed the PCPT risk calculator in the entire validation cohort (0.849 vs 0.779 in area under the receiver operating characteristic curve [AUC] and stratified population. A considerable reduction of unnecessary biopsies (approximately 30%) was also observed when the Huashan risk calculators were used. Thus, we believe that the Huashan risk calculators (especially Huashan risk calculator 1) may have added value for predicting PCa in Chinese population.
Persistent Identifierhttp://hdl.handle.net/10722/314392
ISSN
2021 Impact Factor: 3.054
2020 SCImago Journal Rankings: 0.701
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWu, Yi Shuo-
dc.contributor.authorZhang, Ning-
dc.contributor.authorLiu, Sheng Hua-
dc.contributor.authorXu, Jian Feng-
dc.contributor.authorTong, Shi Jun-
dc.contributor.authorCai, Ye Hua-
dc.contributor.authorZhang, Li Min-
dc.contributor.authorBai, Pei De-
dc.contributor.authorHu, Meng Bo-
dc.contributor.authorJiang, Hao Wen-
dc.contributor.authorNa, Rong-
dc.contributor.authorDing, Qiang-
dc.contributor.authorSun, Ying Hao-
dc.date.accessioned2022-07-20T12:03:55Z-
dc.date.available2022-07-20T12:03:55Z-
dc.date.issued2016-
dc.identifier.citationAsian Journal of Andrology, 2016, v. 18, n. 6, p. 925-929-
dc.identifier.issn1008-682X-
dc.identifier.urihttp://hdl.handle.net/10722/314392-
dc.description.abstractThe performances of the Prostate Cancer Prevention Trial (PCPT) risk calculator and other risk calculators for prostate cancer (PCa) prediction in Chinese populations were poorly understood. We performed this study to build risk calculators (Huashan risk calculators) based on Chinese population and validated the performance of prostate-specific antigen (PSA), PCPT risk calculator, and Huashan risk calculators in a validation cohort. We built Huashan risk calculators based on data from 1059 men who underwent initial prostate biopsy from January 2006 to December 2010 in a training cohort. Then, we validated the performance of PSA, PCPT risk calculator, and Huashan risk calculators in an observational validation study from January 2011 to December 2014. All necessary clinical information were collected before the biopsy. The results showed that Huashan risk calculators 1 and 2 outperformed the PCPT risk calculator for predicting PCa in both entire training cohort and stratified population (with PSA from 2.0 ng ml-1 to 20.0 ng m). In the validation study, Huashan risk calculator 1 still outperformed the PCPT risk calculator in the entire validation cohort (0.849 vs 0.779 in area under the receiver operating characteristic curve [AUC] and stratified population. A considerable reduction of unnecessary biopsies (approximately 30%) was also observed when the Huashan risk calculators were used. Thus, we believe that the Huashan risk calculators (especially Huashan risk calculator 1) may have added value for predicting PCa in Chinese population.-
dc.languageeng-
dc.relation.ispartofAsian Journal of Andrology-
dc.subjectbiopsy-
dc.subjectChina-
dc.subjectprostate cancer-
dc.subjectprostate-specific antigen-
dc.subjectrisk calculator-
dc.titleThe Huashan risk calculators performed better in prediction of prostate cancer in Chinese population: A training study followed by a validation study-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.4103/1008-682X.181192-
dc.identifier.pmid27212127-
dc.identifier.pmcidPMC5109890-
dc.identifier.scopuseid_2-s2.0-84994651164-
dc.identifier.volume18-
dc.identifier.issue6-
dc.identifier.spage925-
dc.identifier.epage929-
dc.identifier.eissn1745-7262-
dc.identifier.isiWOS:000390232000023-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats